Company profile: Adaptimmune
1.1 - Company Overview
Company description
- Provider of T-cell therapies to treat cancer, human immunodeficiency virus, and infectious diseases, including afami-cel, a single-dose T-cell therapy targeting cancer, and lete-cel, a single-dose T-cell therapy in development for treating solid tumors.
Products and services
- Lete-cel: An in-development product delivering a single-dose T-cell treatment for solid tumors, focused on treating cancerous tissues
- T-cell therapies for HIV and infectious diseases: A cellular-immunotherapy program developing T-cell treatments to target human immunodeficiency virus and infectious pathogens
- Afami-cel: A single-dose T-cell therapy targeting cancer, engineered for one-time administration to attack malignant cells
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Adaptimmune
IntraOp
HQ: United States
Website
- Description: Provider of compact, mobile electron therapy devices and platforms for cancer treatment, including Mobetron, a self-shielded electron-beam linear accelerator for intraoperative radiation therapy; FLASH-IQ, delivering UHDR electron beams for preclinical and investigational FLASH radiotherapy; and non-invasive electron therapy for non-melanoma skin cancer.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full IntraOp company profile →
Cernostics
HQ: United States
Website
- Description: Provider of molecular diagnostic tests for cancer, leveraging its patent-protected TissueCypher platform. TissueCypher is a laboratory-developed test that analyzes tissue from Barrett's esophagus biopsies to provide a patient's five-year risk of progression to high-grade dysplasia or esophageal adenocarcinoma.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cernostics company profile →
Insure One
HQ: United States
Website
- Description: Provider of at-home fecal immunochemical tests (FIT) for colorectal cancer screening, using a non-invasive brush-based sample collection to detect lower gastrointestinal bleeding without direct stool handling, with a focus on patient compliance and data privacy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Insure One company profile →
SpringWorks Therapeutics
HQ: United States
Website
- Description: Provider of targeted oncology therapies for cancer and rare diseases, focused on innovative treatments for unmet needs. Portfolio includes nirogacestat, an oral gamma secretase inhibitor for desmoid tumors and in evaluation for ovarian granulosa cell tumors and multiple myeloma; mirdametinib, a MEK inhibitor for NF1-associated plexiform neurofibromas; brimarafenib (BGB-3245), a RAF fusion/dimer inhibitor; and SW-682, a TEAD inhibitor.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full SpringWorks Therapeutics company profile →
Circio
HQ: Norway
Website
- Description: Provider of active immunotherapy cancer vaccines for post-operation treatments, including TG01, a peptide-based vaccine targeting KRAS/RAS driver mutations in clinical trials for RAS-mutated pancreatic cancer, lung cancer, and multiple myeloma, and circVec, a genetic medicine platform producing multifunctional circular RNA from DNA and viral vectors with enhanced, durable protein expression versus classic mRNA systems.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Circio company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Adaptimmune
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Adaptimmune
2.2 - Growth funds investing in similar companies to Adaptimmune
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Adaptimmune
4.2 - Public trading comparable groups for Adaptimmune
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →